



United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

PPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO	
10/619,055	07/14/2003	Yann Echelard	GTC-208	6885	
31904 75	90 12/02/2005		EXAMINER		
GTC BIOTHERAPEUTICS, INC.			NOBLE, MARCIA STEPHENS		
175 CROSSING BOULEVARD, SUITE 410 FRAMINGHAM, MA 01702		310	ART UNIT	PAPER NUMBER	
			1632		

DATE MAILED: 12/02/2005

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)	_
	10/619,055	ECHELARD ET AL.	
Office Action Summary	Examiner	Art Unit	
	Marcia S. Noble	1632	
The MAILING DATE of this communication app Period for Reply	pears on the cover sheet with	the correspondence address	
A SHORTENED STATUTORY PERIOD FOR REPL WHICHEVER IS LONGER, FROM THE MAILING D - Extensions of time may be available under the provisions of 37 CFR 1.1 after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period - Failure to reply within the set or extended period for reply will, by statute Any reply received by the Office later than three months after the mailin earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICA (36(a). In no event, however, may a reply will apply and will expire SIX (6) MONTHS at cause the application to become ABAN	TION. be timely filed from the mailing date of this communication. DONED (35 U.S.C. § 133).	
Status			
1) Responsive to communication(s) filed on	·		
•	action is non-final.		
3) Since this application is in condition for allowa	nce except for formal matters	s, prosecution as to the merits is	
closed in accordance with the practice under			
Disposition of Claims			
4) Claim(s) 1-25 is/are pending in the application	l.		
4a) Of the above claim(s) is/are withdra	wn from consideration.		
5) Claim(s) is/are allowed.			
6) Claim(s) is/are rejected.			
7) Claim(s) is/are objected to.			
8) Claim(s) <u>1-25</u> are subject to restriction and/or	election requirement.		
Application Papers			
9)☐ The specification is objected to by the Examine	er.		
10) The drawing(s) filed on is/are: a) acc	cepted or b) objected to by	the Examiner.	
Applicant may not request that any objection to the	drawing(s) be held in abeyance	. See 37 CFR 1.85(a).	
Replacement drawing sheet(s) including the correct	ction is required if the drawing(s)	is objected to. See 37 CFR 1.121(d).	
11)☐ The oath or declaration is objected to by the E	xaminer. Note the attached C	Office Action or form PTO-152.	
Priority under 35 U.S.C. § 119			
12) Acknowledgment is made of a claim for foreign a) All b) Some * c) None of:	n priority under 35 U.S.C. § 1	19(a)-(d) or (f).	
 Certified copies of the priority document 			
Certified copies of the priority documen			
3. Copies of the certified copies of the price		ceived in this National Stage	
application from the International Burea			
* See the attached detailed Office action for a lis	t of the certified copies not re	ceivea.	
Attachment(s) 1) Notice of References Cited (PTO-892)	4) T Interview Sun	nmary (PTO-413)	
2) Notice of Preferences Cited (PTO-692) Notice of Draftsperson's Patent Drawing Review (PTO-948)	Paper No(s)/	Mail Date	
3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08 Paper No(s)/Mail Date	5) Notice of Info 6) Other:	mal Patent Application (PTO-152)	

Page 2

Application/Control Number: 10/619,055

Art Unit: 1632

DETAILED ACTION

1. Claims 1-25 are pending.

Election/Restrictions

Restriction to one of the following inventions is required under 35 U.S.C. 121:

- I. Claims 1-11, 14, 17, and 22-24, drawn to a method of producing homozygous transgenic animals using an embryo donor cell, classified in class 800, subclass 24.
- II. Claims 14-19, drawn to a method of producing homozygous transgenic animals using non-quiescent somatic donor cells, classified in class 800, subclass 21.
- III. Claims 12, 13, and 19, drawn to resultant transgenic offspring, classified in class 800, subclass 8.
- IV. Claims 20-24, drawn to a method of developing a functional organ transplant using homozygous transgenic cell lines, classified in class 800, subclass 3.
- V. Claim 25, drawn to resultant milk derived from the resultant homozygous transgenic offspring, classified in class 800, subclass 7.

The inventions are distinct, each from the other because of the following reasons:

2. Inventions I, II, and IV are patentably distinct inventions. Inventions are distinct if it can be shown that they are not disclosed as capable of use together and they have

Art Unit: 1632

different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01).

In the instant case, group I and II are distinct from each other because the methods require distinct starting materials. Group I uses embryo donor cells and group II use non-quiescent somatic cells. Embryonic donor cell are naturally totipotent and undifferentiated and therefore can be transferred into another embryo directly whereas somatic cells must under reprogramming methods to return it to the undifferentiated, totipotent state first before use in nuclear transfer. Therefore group I and II are distinct because group II requires different and additional steps not required by group I. Group I and II are distinct from group IV because group IV will use the homozygous cells in a different methodology to produce a different outcome, a functional organ for transplant.

Inventions of III and V are patentable distinct. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case, III is drawn to homozygous transgenic offspring which is biologically distinct from V, drawn to milk from resultant homozygous transgenic animals. Milk have a chemical and biological distinct structure and function than transgenic offspring.

The methods of I, II, and IV and products of III and V are related as process of making and process of using the product. The use as claimed cannot be practiced with a materially different product. Since the product is not allowable, restriction is proper

Application/Control Number: 10/619,055 Page 4

Art Unit: 1632

between said method of making and method of using. The product claim will be examined along with the elected invention (MPEP § 806.05(i)).

Homozygous transgenic animals can be produced by microinjection of a transgene, followed by embryo transfer and selective breeding of transgenic offspring.

Also cell from this method of producing transgenic animals can be used to produce transplantable organs.

Because these inventions are distinct for the reasons given above and have acquired a separate status in the art because of their recognized divergent subject matter, restriction for examination purposes as indicated is proper.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Marcia S. Noble whose telephone number is (571) 272-5545. The examiner can normally be reached on M-F 9 to 5:30.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Ram Shukla can be reached on (571) 272-0735. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

- Joe Water

Application/Control Number: 10/619,055 Page 5

Art Unit: 1632

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Marcia S. Noble

Joe World